Inventor · disambiguated record
Seema Kantak
Also filed as: KANTAK SEEMA
3 granted patents·9 pending applications·41 citations·filing 2008–2023
70Inventor score
Top patents by PatentIndex Score
12 records- 0188US10010587B2IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibodyNEKTAR THERAPEUTICS·Filed 2015·Granted Jul 3, 2018·11 cites·15 claims
- 0288US8216571B2Fully human anti-VEGF antibodies and methods of usingRAMACHANDRA SUMANT·Filed 2008·Granted Jul 10, 2012·29 cites·21 claims
- 0376US10786552B2Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibodyNEKTAR THERAPEUTICS·Filed 2018·Granted Sep 29, 2020·1 cites·18 claims
- 0462US2020368321A1Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibodyNEKTAR THERAPEUTICS·Filed 2020·Application pending·0 cites
- 0562US2025326858A15t4 binding agents and uses thereofEXELIXIS INC·Filed 2023·Application pending·0 cites
- 0660US2025197502A1Multispecific binding agents and uses thereofEXELIXIS INC·Filed 2023·Application pending·0 cites
- 0760US2025295803A15t4 antibody-drug conjugates and uses thereofEXELIXIS INC·Filed 2023·Application pending·0 cites
- 0859US2011002934A1Uses of anti-cd40 antibodiesNOVARTIS AG·Filed 2008·Application pending·0 cites
- 0950US2023357391A1Cd47 binding agents and uses thereofEXELIXIS INC·Filed 2021·Application pending·0 cites
- 1050US2023303699A1Pd-l1 binding agents and uses thereofEXELIXIS INC·Filed 2021·Application pending·0 cites
- 1150US2024010751A1Multispecific binding agents and uses thereofEXELIXIS INC·Filed 2021·Application pending·0 cites
- 1238US2017112941A1Ve-cadherin binding bioconjugateSYMIC IP LLC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →